Unadjusted relative risks of any early vomiting (95% CI), by age group.

<p>Unadjusted relative risks of any early vomiting (95% CI), by age group.</p

Trial participant baseline characteristics.

<p>Trial participant baseline characteristics.</p

Frequency of adverse events.

<p>Frequency of adverse events.</p

Serious neuropsychiatric events associated with MQ treatment.

<p>Serious neuropsychiatric events associated with MQ treatment.</p

Vomiting frequency (by episode) directly (<1 h) after mefloquine (MQ) administration.

<p>Frequencies are by age group (<b>A-C</b>) and day of treatment.</p

Overview of studies evaluated for neuropsychiatric adverse events.

<p>MSF: Médecins sans Frontières; SMRU: Shoklo Malaria Research Unit. These studies have been published: [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0168780#pone.0168780.ref013" target="_blank">13</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0168780#pone.0168780.ref014" target="_blank">14</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0168780#pone.0168780.ref034" target="_blank">34</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0168780#pone.0168780.ref048" target="_blank">48</a>].</p

The timing and total dose of MQ (mefloquine) and artesunate from 18 SMRU studies.

<p>The timing and total dose of MQ (mefloquine) and artesunate from 18 SMRU studies.</p

Two-way sensitivity analysis results showing the impact of changes in the level of adherence to primaquine regimens.

<p>Green represents disability-adjusted life-years (DALYs) averted by the screening strategy for a cohort of 1000 individuals. For costs, yellow indicates increased costs and blue indicates cost savings for the screening strategy for one individual. For net monetary benefit (<i>NMB</i>), purple indicates scenarios where the screening strategy would be cost-effective at a threshold of US$500 (<i>T</i>) where <i>NMB = T × ΔDALYs– ΔCosts</i>.</p

Model diagram of strategies for <i>P</i>. <i>vivax</i> treatment in females.

<p>Model diagram of strategies for <i>P</i>. <i>vivax</i> treatment in females.</p

Costs and disability adjusted life year (DALY) results over one year per primary episode treated in the base case analysis and probabilistic sensitivity analysis (PSA).

<p>All costs are in 2014 United States Dollars.</p